

MD Anderson Ovarian SPORE publications – 2013

1. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. **Src activation by beta-adrenoreceptors is a key switch for tumour metastasis.** Nat Commun 4:1403, 2013. PMID: 23360994; PMCID: PMC3561638.
2. Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. **Neuroendocrine influences on cancer progression.** Brain Behav Immun 30 Suppl:S19-25, 2013. PMID: 22728325; PMCID: PMC3467346.
3. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. **Nanotechnology in cancer therapy.** J Drug Target 21(10):904-13, 2013. PMID: 24079419; PMCID: PMC4057038.
4. Baggerly K. **More data, please!** Clin Chem 59(3):459-61, 2013. PMID: 23340443; PMCID: PMC3746981.
5. Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. **Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.** PLoS One 8(11):e79167, 2013. PMID: 24236104; PMCID: PMC3827285.
6. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J. **CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.** Int J Gynecol Cancer 23(5):815-22, 2013. PMID: 23669443; PMCID: PMC3760786.
7. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. **Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.** Hum Pathol 44(11):2373-84, 2013. PMID: 23850493; PMCID: PMC3797876.
8. Coleman RL, Monk BJ, Sood AK, Herzog TJ. **Latest research and treatment of advanced-stage epithelial ovarian cancer.** Nat Rev Clin Oncol 10(4):211-24, 2013. PMID: 23381004; PMCID: PMC3786558.
9. Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M, Marini FC. **Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.** Cytotherapy 15(1):20-32, 2013. PMID: 23260083; PMCID: PMC3709838.
10. Diamandis EP, Bast RC Jr, Gold P, Chu TM, Magnani JL. **Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.** Clin Chem 59(1):22-31, 2013. PMID: 23204222; PMCID: PMC3983776.
11. Diamandis EP, Bast RC Jr, Lopez-Otin C. **Conquering cancer in our lifetime: new diagnostic and therapeutic trends.** Clin Chem 59(1):1-3, 2013. PMID: 23204223.
12. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheeler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. **Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.** Invest New Drugs 31(5):1192-200, 2013. PMID: 23907406; PMCID: PMC3809091.
13. Hawkins SM, Loomans HA, Wan YW, Ghosh-Choudhury T, Coffey D, Xiao W, Liu Z, Sangi-Haghpeykar H, Anderson ML. **Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer.** J Clin Endocrinol Metab 98(7):E1152-62, 2013. PMID: 23690307; PMCID: PMC3701283.

14. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. **Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.** *Gynecol Oncol* 128(3):506-11, 2013. PMID: 23200915; PMCID: PMC3645276.
15. Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji H, McCrea PD, Park JI. **PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation.** *Mol Cell* 52(2):193-205, 2013. PMID: 24055345; PMCID: PMC4040269.
16. Jung HY, Wang X, Jun S, Park JI. **Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.** *J Biol Chem* 288(10):7252-62, 2013. PMID: 23362280; PMCID: PMC3591633.
17. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. **Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.** *J Natl Cancer Inst* 105(19):1485-95, 2013. PMID: 24062525; PMCID: PMC3787907.
18. Klempner SJ, Myers AP, Mills GB, Westin SN. **Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.** *Expert Opin Pharmacother* 14(16):2171-82, 2013. PMID: 23937415.
19. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK. **Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.** *Front Oncol* 3:58, 2013. PMID: 23519775; PMCID: PMC3602963.
20. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. **Targeting SRC and tubulin in mucinous ovarian carcinoma.** *Clin Cancer Res* 19(23):6532-43, 2013. PMID: 24100628; PMCID: PMC3852199.
21. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr. **A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.** *Cancer* 119(19):3454-61, 2013. PMID: 23983047; PMCID: PMC3982191.
22. Lu Z, Bast RC Jr. **The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms.** *Cell Adh Migr* 7(2):232-6, 2013. PMID: 23357870; PMCID: PMC3954037.
23. Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, 3rd, Mendez L, Collins K, Sood AK. **Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.** *Gynecol Oncol* 131(3):667-73, 2013. PMID: 24096110; PMCID: PMC3882020.
24. Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC Jr, Hua K, Feng W. **Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.** *Epigenetics* 8(12):1330-46, 2013. PMID: 24135786; PMCID: PMC3933493.
25. Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills GB, Chen K. **CanDrA: cancer-specific driver missense mutation annotation with optimized features.** *PLoS One* 8(10):e77945, 2013. PMID: 24205039; PMCID: PMC3813554.
26. Masiero M, Simoes FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. **A core human primary tumor angiogenesis signature identifies the**

endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. *Cancer Cell* 24(2):229-41, 2013. PMID: 23871637; PMCID: PMC3743050.

27. Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA. **Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes.** *PLoS One* 8(11):e80314, 2013. PMID: 24303006; PMCID: PMC3841174.
28. Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KP. **A new method for stranded whole transcriptome RNA-seq.** *Methods* 63(2):126-34, 2013. PMID: 23557989; PMCID: PMC3739992.
29. Miyake TM, Sood AK, Coleman RL. **Contemporary use of bevacizumab in ovarian cancer.** *Expert Opin Biol Ther* 13(2):283-94, 2013. PMID: 23190436; PMCID: PMC3799801.
30. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. **ATP11B mediates platinum resistance in ovarian cancer.** *J Clin Invest* 123(5):2119-30, 2013. PMID: 23585472; PMCID: PMC3635722.
31. Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. **Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.** *Neoplasia* 15(5):502-10, 2013. PMID: 23633922; PMCID: PMC3638353.
32. Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. **Why stress is BAD for cancer patients.** *J Clin Invest* 123(2):558-60, 2013. PMID: 23348736; PMCID: PMC3561841.
33. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. **Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.** *Cancer Discov* 3(11):1302-15, 2013. PMID: 24002999; PMCID: PMC3855315.
34. Nolen BM, Lokshin AE. **Biomarker testing for ovarian cancer: clinical utility of multiplex assays.** *Mol Diagn Ther* 17(3):139-46, 2013. PMID: 23552992; PMCID: PMC3670781.
35. Nolen BM, Orlichenko LS, Marrangoni A, Velikokhatnaya L, Prosser D, Grizzle WE, Ho K, Jenkins FJ, Bovbjerg DH, Lokshin AE. **An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.** *PLoS One* 8(5):e63368, 2013. PMID: 23723977; PMCID: PMC3665773.
36. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH. **Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance.** *PLoS One* 8(12):e81859, 2013. PMID: 24312594; PMCID: PMC3847080.
37. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. **Tumour angiogenesis regulation by the miR-200 family.** *Nat Commun* 4:2427, 2013. PMID: 24018975; PMCID: PMC3904438.

38. Romero I, Sun CC, Wong KK, Bast RC Jr, Gershenson DM. **Low-grade serous carcinoma: new concepts and emerging therapies.** *Gynecol Oncol* 130(3):660-6, 2013. PMID: 23707670.
39. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. **Interleukin-1beta promotes ovarian tumorigenesis through a p53/NF-kappaB-mediated inflammatory response in stromal fibroblasts.** *Neoplasia* 15(4):409-20, 2013. PMID: 23555186; PMCID: PMC3612913.
40. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. **A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.** *Gynecol Oncol* 129(1):86-91, 2013. PMID: 23321064; PMCID: PMC3712785.
41. Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. **Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.** *Cancer Lett* 330(2):123-9, 2013. PMID: 22776561; PMCID: PMC3498611.
42. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. **Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.** *Clin Cancer Res* 19(7):1806-15, 2013. PMID: 23386691; PMCID: PMC3618564.
43. Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. **Impact of cardiovascular comorbidity on ovarian cancer mortality.** *Cancer Epidemiol Biomarkers Prev* 22(11):2102-9, 2013. PMID: 24045927; PMCID: PMC3830519.
44. Simmons AR, Baggerly K, Bast RC Jr. **The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.** *Oncology (Williston Park)* 27(6):548-56, 2013. PMID: 23909069.
45. Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK. **PAX2 Expression in Ovarian Cancer.** *Int J Mol Sci* 14(3):6090-105, 2013. PMID: 23502471; PMCID: PMC3634442.
46. Spaeth EL, Booth CM, Marini FC. **Quantitative multispectral analysis following fluorescent tissue transplant for visualization of cell origins, types, and interactions.** *J Vis Exp* (79):e50385, 2013. PMID: 24084599.
47. Spaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. **Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment.** *Cancer Res* 73(17):5347-59, 2013. PMID: 23838935; PMCID: PMC3767181.
48. Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC Jr, Yu Y, Feng Y. **FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.** *Endocr Relat Cancer* 20(3):415-29, 2013. PMID: 23580589; PMCID: PMC3669658.
49. Thaker PH, Sood AK, Ramondetta LM. **Importance of adrenergic pathways in women's cancers.** *Cancer Biomark* 13(3):145-54, 2013. PMID: 23912486.
50. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK. **KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.** *J Pathol* 231(4):449-56, 2013. PMID: 24549645.

51. Wan G, Hu X, Liu Y, Han C, Sood AK, Calin GA, Zhang X, Lu X. **A novel non-coding RNA IncRNA-JADE connects DNA damage signalling to histone H4 acetylation.** EMBO J 32(21):2833-47, 2013. PMID: 24097061; PMCID: PMC3817469.
52. Wang H, Heijnen CJ, van Velthoven CT, Willems HL, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars A. **Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.** J Clin Invest 123(12):5023-34, 2013. PMID: 24231349; PMCID: PMC3859388.
53. Wang X, Singh S, Jung HY, Yang G, Jun S, Sastry KJ, Park JI. **HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex.** J Biol Chem 288(22):15474-80, 2013. PMID: 23612978; PMCID: PMC3668709.
54. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. **FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.** J Clin Invest 123(10):4435-48, 2013. PMID: 24018557; PMCID: PMC3784549.
55. Westin SN, Herzog TJ, Coleman RL. **Investigational agents in development for the treatment of ovarian cancer.** Invest New Drugs 31(1):213-29, 2013. PMID: 22661305.
56. Westin SN, Mills GB, Myers AP. **Repurposing the Pap smear: one step closer to gynecologic cancer screening.** Sci Transl Med 5(167):167ps1, 2013. PMID: 23303602; PMCID: PMC3824959.
57. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. **Poor survival with wild-type TP53 ovarian cancer?** Gynecol Oncol 130(3):565-9, 2013. PMID: 23800698; PMCID: PMC4059202.
58. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. **Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.** Cancer Cell 23(2):186-99, 2013. PMID: 23410973; PMCID: PMC3603369.
59. Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih Ie M, Wong KK, Gershenson DM, Liu J. **RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis.** Int J Cancer 133(2):275-85, 2013. PMID: 23319376; PMCID: PMC3883442.
60. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. **Predicting time to ovarian carcinoma recurrence using protein markers.** J Clin Invest 123(9):3740-50, 2013. PMID: 23945238; PMCID: PMC3754259.
61. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. **TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.** Cancer Res 73(16):5016-28, 2013. PMID: 23824740; PMCID: PMC3745588.
62. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. **Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.** Clin Cancer Res 19(4):809-20, 2013. PMID: 23344261; PMCID: PMC3577959.
63. Zhang J, Chang B, Liu J. **CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.** Hum Pathol 44(9):1882-9, 2013. PMID: 23664487; PMCID: PMC3752324.
64. Zhang S, Mercado-Uribe I, Hanash S, Liu J. **iTRAQ-based proteomic analysis of polyploid giant cancer cells and budding progeny cells reveals several distinct pathways for ovarian cancer**

development. PLoS One 8(11):e80120, 2013. PMID: 24348907; PMCID: PMC3858113.

65. Zhang S, Mercado-Uribe I, Liu J. **Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo.** Cancer Lett 333(2):205-12, 2013. PMID: 23376638; PMCID: PMC3760787.
66. Zhang Z, Zhu Y, Lai Y, Wu X, Feng Z, Yu Y, Bast RC Jr, Wan X, Xi X, Feng Y. **Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.** Int J Oncol 43(4):1194-204, 2013. PMID: 23921511; PMCID: PMC3981007.
67. Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. **Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.** Clin Cancer Res 19(1):170-82, 2013. PMID: 23147994; PMCID: PMC3537868.